1. Home
  2. ACHR vs TVTX Comparison

ACHR vs TVTX Comparison

Compare ACHR & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Archer Aviation Inc.

ACHR

Archer Aviation Inc.

HOLD

Current Price

$5.53

Market Cap

4.5B

Sector

Industrials

ML Signal

HOLD

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$65.79

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACHR
TVTX
Founded
2018
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
5.3B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
ACHR
TVTX
Price
$5.53
$65.79
Analyst Decision
Buy
Strong Buy
Analyst Count
6
13
Target Price
$12.00
$40.62
AVG Volume (30 Days)
23.6M
1.2M
Earning Date
05-11-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
30.28
92.89
EPS
N/A
N/A
Revenue
$300,000.00
N/A
Revenue This Year
$4,986.67
$44.76
Revenue Next Year
$876.87
$35.51
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.30
$22.06
52 Week High
$14.62
$68.73

Technical Indicators

Market Signals
Indicator
ACHR
TVTX
Relative Strength Index (RSI) 44.19 57.68
Support Level $4.87 $53.76
Resistance Level $5.59 N/A
Average True Range (ATR) 0.22 2.12
MACD -0.08 -0.32
Stochastic Oscillator 11.88 53.71

Price Performance

Historical Comparison
ACHR
TVTX

About ACHR Archer Aviation Inc.

Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner. The company is building a platform to deliver aircraft, technologies, and services to customers world-wide across commercial and defense sectors.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: